Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.37 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.33 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.33 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6744463 | 0.85 | HPGD (0.43) | HSD17B10ALDH1A1KMT2ALMNAPKM | |
| SCHEMBL6747401 | 0.67 | PTK2 (0.38) | MAPTP2RY12KMT2AHTR7RECQL | |
| SCHEMBL6745728 | 0.67 | F2 (0.54) | MAPTALDH1A1KMT2ALMNA | |
| SCHEMBL5335214 | 0.60 | MAPT (0.63) | MAPTALDH1A1KMT2ALMNA | |
| SCHEMBL11610564 | 0.59 | MAPT (0.48) | MAPTKMT2ALMNARECQL | |
| SCHEMBL18827686 | 0.58 | TDP1 (0.58) | MAPTPOLBALDH1A1KMT2ALMNA | |
| SCHEMBL31538461 | 0.57 | KMT2A (0.61) | MAPTHSD17B10ALDH1A1KMT2ALMNA | |
| SCHEMBL19581034 | 0.57 | KMT2A (0.60) | MAPTPOLBALDH1A1KMT2ALMNA | |
| SCHEMBL8307871 | 0.57 | HPGD (0.48) | POLBLMNANPSR1 | |
| SCHEMBL663552 | 0.57 | KMT2A (0.76) | MAPTALDH1A1KMT2ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040043984-A1 | 3,4-Dihydroquinolin-2-one, 5,6-fused oxazin-3-one, and 5,6-fused thiazin-3-one derivatives as matrix metalloproteinase inhibitors | O'BRIEN PATRICK MICHAEL (US) | 2004-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040043984-A1 | 3,4-Dihydroquinolin-2-one, 5,6-fused oxazin-3-one, and 5,6-fused thiazin-3-one derivatives as matrix metalloproteinase inhibitors | MMP13, MMP9, MMP3 | MAPT 1797/4885P2RY12 2477/4885POLB 1227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.